Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
August 18, 2022 09:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
SAB_Logo.png
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
December 01, 2021 07:00 ET | SAB Biotherapeutics, Inc.
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
SAB_Logo.png
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
October 25, 2021 07:40 ET | Sab Biotherapeutics, Inc.
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D.,...
NSPR Logo-3.jpg
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
April 29, 2021 06:00 ET | InspireMD Inc.
TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by...